About Genocea

Genocea is developing therapeutics at the forefront of the T cell revolution. T cells are increasingly recognized as a critical element of the body’s protective immune response to a wide range of pathogens and diseases.

While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully leverage ATLAS™, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses, enabling the rapid development of therapeutic vaccines that stimulate human protective immunity. We have advanced our lead candidate, GEN-003, a novel T cell-enabled immunotherapy for genital herpes, into Phase 2 clinical development, while also exploring earlier-stage candidates in immuno-oncology.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$4.78
- 0.02 (-0.42%)


0.02M

Volume

$4.81

Day High

$4.70

Day Low

Feb 23, 2017 ET on 10:51 AM Delayed at least 20 minutes.

Stock Chart